Circulating tumor DNA and circulating tumor cells as predictor of outcome in the PRODIGE14-ACCORD21-METHEP2 phase II trial

François-Clément Bidard 1 M. Ychou 2 J. Madic 1 A. Saliou 1 O. Bouche 3 M. Rivoire 4 François Ghiringhelli 5 E. Francois 6 R. Guimbaud 7 L. Mineur F. Khemissa-Akouz 8 T. Mazard 2 D. Moussata 9 W. Cacheux, 1 C. Proudhon, 1 M-H. Stern 10 J-Y. Pierga 1 T. Stanbury S. Thezenas 2 P. Mariani 1
1 Institut Curie
2 ICM - UNICANCER - Institut régional du Cancer [Montpellier]
3 CHU Reims - Centre Hospitalier Universitaire de Reims
4 Centre Léon Bérard [Lyon]
5 LNC - Lipides - Nutrition - Cancer (U866)
6 Centre Antoine Lacassagne
7 CHU Toulouse [Toulouse]
8 Centre Hospitalier Saint Jean de Perpignan
9 CHLS - Centre Hospitalier Lyon Sud [CHU - HCL]
10 U830 - Unité de génétique et biologie des cancers
Abstract : Background: We prospectively detected circulating tumor DNA (ctDNA) and circulating tumor cells (CTC) levels in patients (pts) included in the PRODIGE14-ACCORD21-METHEP2 randomized phase II trial. Methods: The trial enrolled colorectal cancer pts with potentially resectable liver metastases & no prior treatment; the primary endpoint was the rate of R0/R1 liver metastases resection achieved by 1st line regimen (targeted therapies & bi- vs tri-chemotherapy; Ychou, ASCO 2016). Blood samples were collected at inclusion, after 1 month of therapy and before any liver metastases surgery. CTCs (CellSearch) & ctDNA (ddPCR, BioRad) were detected in an experienced laboratory (Inst. Curie). Results: 153 pts had at least one blood analysis. High CTC count (≥3 CTC/7.5ml) was detected in 25/132 pts (19%) at baseline and associated with synchronous...
Keywords : Tumor DNA PRODIGE14-ACCORD21-METHEP2
Type de document :
Communication dans un congrès
the 41st ESMO Congress (ESMO 2016), Oct 2016, Copenhague, Denmark. Annals of oncology, 27 (suppl_6), pp.456O, 2016, Abstract Book of the 41st ESMO Congress (ESMO 2016). 〈https://academic.oup.com/annonc/article-abstract/27/suppl_6/456O/2799195/Circulating-tumor-DNA-and-circulating-tumor-cells?redirectedFrom=fulltext〉. 〈10.1093/annonc/mdw370.5〉
Liste complète des métadonnées
https://hal-univ-bourgogne.archives-ouvertes.fr/hal-01490996
Contributeur : Lnc - Université de Bourgogne <>
Soumis le : jeudi 16 mars 2017 - 11:26:14
Dernière modification le : mercredi 5 septembre 2018 - 15:32:02

Identifiants

Collections

CURIE | FNCLCC | PSL | LNC-UMR866 | UNIV-PARIS5 | VALDAURELLE | LACASSAGNE | USPC | HCL | CHLS | ENSBANA

Citation

François-Clément Bidard, M. Ychou, J. Madic, A. Saliou, O. Bouche, et al.. Circulating tumor DNA and circulating tumor cells as predictor of outcome in the PRODIGE14-ACCORD21-METHEP2 phase II trial. the 41st ESMO Congress (ESMO 2016), Oct 2016, Copenhague, Denmark. Annals of oncology, 27 (suppl_6), pp.456O, 2016, Abstract Book of the 41st ESMO Congress (ESMO 2016). 〈https://academic.oup.com/annonc/article-abstract/27/suppl_6/456O/2799195/Circulating-tumor-DNA-and-circulating-tumor-cells?redirectedFrom=fulltext〉. 〈10.1093/annonc/mdw370.5〉. 〈hal-01490996〉

Exporter

BibTeX TEI DC DCterms EndNote

Partager

Métriques

Consultations de la notice

123

Contact

support.ccsd.cnrs.fr
hal.support@ccsd.cnrs.fr
Logo CCSD